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Abstract
Background: Genetic factors play a role in chronic obstructive pulmonary disease (COPD) but are poorly
understood. A number of candidate genes have been proposed on the basis of the pathogenesis of COPD. These
include the matrix metalloproteinase (MMP) genes which play a role in tissue remodelling and fit in with the
protease - antiprotease imbalance theory for the cause of COPD. Previous genetic studies of MMPs in COPD have
had inadequate coverage of the genes, and have reported conflicting associations of both single nucleotide
polymorphisms (SNPs) and SNP haplotypes, plausibly due to under-powered studies.
Methods: To address these issues we genotyped 26 SNPs, providing comprehensive coverage of reported SNP
variation, in MMPs- 1, 9 and 12 from 977 COPD patients and 876 non-diseased smokers of European descent and
evaluated their association with disease singly and in haplotype combinations. We used logistic regression to
adjust for age, gender, centre and smoking history.
Results: Haplotypes of two SNPs in MMP-12 (rs652438 and rs2276109), showed an association with severe/very
severe disease, corresponding to GOLD Stages III and IV.
Conclusions: Those with the common A-A haplotype for these two SNPs were at greater risk of developing
severe/very severe disease (p = 0.0039) while possession of the minor G variants at either SNP locus had a
protective effect (adjusted odds ratio of 0.76; 95% CI 0.61 - 0.94). The A-A haplotype was also associated with
significantly lower predicted FEV1 (42.62% versus 44.79%; p = 0.0129). This implicates haplotypes of MMP-12 as
modifiers of disease severity.
Background
Chronic Obstructive Pulmonary Disease (COPD) is a
major cause of morbidity and mortality worldwide. The
World Health Organisation’s Global Burden of Disease
and Risk Factors project estimates that in 2001, COPD
was the fifth leading cause of death in high-income
countries and the sixth leading cause of death in coun-
tries of low and middle income [1]. Cigarette smoking is
the main aetiological risk factor in disease development.
However, only about 10 - 20% of smokers develop clini-
cally significant COPD though this may be an under-
estimate [2]. Furthermore, there is variability between
smokers who have similar levels of smoke exposure,
with many developing milder forms of the disease [3].
These observations suggest that underlying genetic fac-
tors contribute to either disease susceptibility or
protection.
A widely accepted hypothesis of COPD causation is an
imbalance of proteolytic enzymes and their inhibitors
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based on the observation that severe alpha1-antitrypsin
deficiency predisposes cigarette smokers to the develop-
ment of pulmonary emphysema in early adult life. This
is thought to be due to uninhibited neutrophil elastase
(NE) activity degrading elastin, a major component of
lung connective tissue [4]. There are a number of other
proteolytic enzymes also capable of degrading elastin,
most particularly the matrix metalloproteinases (MMPs),
a family of potent proteinases that degrade all the major
protein components of the extra-cellular matrix (ECM).
MMPs play a key role in tissue remodelling and repair
and there is significant evidence that members of the
MMP family may also play an important role in COPD
pathology. Transgenic mice over-expressing MMP-1
develop emphysema [5], whilst MMP-12 knockout mice
are protected from emphysema despite prolonged cigar-
ette smoke exposure[6], implicating MMP-12 as a com-
pelling emphysema determinant in this model. In COPD
patients a range of studies implicate MMPs in the
pathogenesis of the disease [7-12]. A number of studies
have reported associations of genetic variants in MMPs-
1, 9 and 12 with COPD or related phenotypes. MMP-1
and MMP-12 are located in close proximity on chromo-
some 11 and MMP-9 is located on chromosome 20.
Reported associations of these genes with COPD include
associations of haplotypes of MMPs- 1 and 12 with rate
of decline in lung function [13] in Caucasians and asso-
ciation of an MMP-9 promoter polymorphism with
emphysema in a Japanese population [14]. However,
there are conflicting data on the potential involvement
of MMP variation in COPD. This likely reflects a num-
ber of issues relating to false positives in case- control
studies or a lack of power due to relatively small sample
size and the limited number of single nucleotide poly-
morphisms (SNPs) investigated, MMP 1, 9 and 12 stu-
dies are summarised in table 1. Other issues that
contribute to lack of reproducibility include variation in
the definition of cases and controls, improper matching
of cases and controls and ethnic differences [15]. The
results therefore need to be interpreted with caution.
To address the major issues, a European cohort of 977
Caucasian COPD patients and 876 non-diseased smok-
ing controls with complete genotyping information was
used to evaluate the relationship of 26 SNPs within
MMPs- 1, 9 and 12 with COPD and to investigate asso-
ciations with GOLD -defined severity phenotypes. These
tagging SNPs provide coverage of most of the variation
within the MMP genes.
Methods
Subjects
COPD and non-diseased smoking control subjects were
recruited from six European centres. Only white Cauca-
sians were recruited. Study approval was obtained from
appropriate local committees to each recruitment cen-
tre. Informed consent was obtained from all subjects.
The resource of COPD patients and non-diseased smok-
ing controls has been described previously [16-19] and
is one of the largest reported to date. The number of
subjects recruited from each centre was as follows. Bar-
celona (Spain): 70 controls and 138 cases; Bristol (UK):
152 controls and 129 cases; Dublin (Ireland): 195 con-
trols and 196 cases; Edinburgh (UK): 81 controls and
168 cases; Leiden (the Netherlands): 216 controls and
188 cases; and Pisa (Italy): 198 controls and 198 cases. It
should be noted that the total resource consisted of
1017 COPD patients and 912 controls. If strict criteria
for genotyping were not met or assay design proved dif-
ficult, results were not included in the present analysis
to minimise potential errors. This resulted in completed
unequivocal genotypes in 977 COPD patients and 876
controls.
Briefly, recruitment criteria were agreed by a panel of
respiratory physicians with an interest in COPD and
included a firm clinical diagnosis of COPD; airflow lim-
itation as indicated by (Forced Expiratory Volume in 1
Second) FEV1 ≤ 70% normal predicted values and FEV1/
(Forced Vital Capacity) FVC < 0.7; no significant reversi-
bility with salbutamol (≥ 200 μg) and a smoking history
of ≥ 20 pack years with matched smoking history for
the controls. FEV1 is measured using a spirometer, it is
the maximum volume of air that can be forcibly
breathed out in one second after full inspiration. FVC is
the maximum volume of air that can be forcibly
breathed out after full inspiration.
Patients were excluded from the study if they had an
established diagnosis of asthma, lung cancer, history of
atopy, known AAT deficiency or a serum AAT level of
less than 1.0 g/L. Patients with acute exacerbations four
weeks preceding study assessment were also excluded.
This was an agreed part of the protocol to enable future
studies, where appropriate, to investigate correlations of
genotypes with quantitative traits such as lung function
or concentrations of analytes in biological fluids. We did
not recruit any patients with Global Obstructive Lung
Disease (GOLD) Stage I. Disease severity was classified
according to GOLD as follows: GOLD Stage II (moder-
ate disease): FEV1/FVC ratio of < 0.70 and FEV1 pre-
dicted ≥ 50% and < 80%; GOLD Stage III (severe
disease): FEV1/FVC ratio of < 0.70 and FEV1 predicted
≥ 30% and < 50%; and GOLD Stage IV (very severe dis-
ease): FEV1/FVC ratio of < 0.70 and FEV1 predicted <
30% [20].
Control subjects with no evidence of airflow obstruc-
tion (FEV1 and FVC ≥ 80% and FEV1/FVC > 0.70) were
recruited at each centre with attempted matching to
COPD patients for ethnicity, age, gender and smoking
history. Exclusion criteria were as described for cases
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and additionally included family history of COPD. How-
ever, complete matching was not achieved due to a high
proportion of smokers aged 65 or over having evidence
of some pulmonary obstruction, thereby excluding them
from recruitment as controls.
We compared the frequencies of MMP SNPs for each
centre in cases and controls to look for population stra-
tification. For the genes under study, population stratifi-
cation would have been reflected in different frequencies
in the centre to centre comparisons. No such differences
were observed. These findings are in keeping with pre-
vious observations on this sample set [19] and with data
obtained from British samples reported by the Well-
come Trust Case Control Consortium in genome- wide
association studies where stratification has been shown
to be not as significant an issue in the British population
as previously thought [21]; similar findings are likely for
western European populations.
Study Population Characteristics
The study population characteristics are summarised in
Table 2. Despite attempts to match cases and controls
there were significant differences observed and
adjustments were made by logistic regression to take
this into account in the statistical analysis. The charac-
teristics of recruited COPD patients across the GOLD
severity categories are shown in Table 3.
Power Calculations
Using Quanto software for the power calculations, with
an autosomal dominant model, this study has 80%
power to detect an odds ratio of 1.5 with an allele fre-
quency of 0.1.
SNP Selection and Haplotypes
SNP identification within MMPs- 1, 9 and 12 genes was
carried out using information obtained from a
Table 1 Previous association studies performed in COPD
Author
(Year)
Case Control Population Gene
(Polymorphism)
rs
number
Findings
Minesmatu et
al (2001) [14]
45 COPD,
emphysema on
CT-Scan
65 Smokers,
No emphysema on
CT-Scan
Japanese MMP9 (-1562C/T) rs3918242 T allele with Emphysema
DLco/VA lower and emphysemous changes
distinct with C/T and T/T
Joos et al
(2002) [13]
284 fast rate of
lung function
decline
306 slow rate of
lung function
decline
Caucasian
(USA)
MMP1 (-1607G/
GG)
MMP9 (CA
Repeat)
MMP9 (-1562C/T)
MMP12 (-82A/G)
MMP12 (357Asn/
Ser)
rs1799750
N/A
rs3918242
rs2276109
rs652438
-1607GG associated with fast rate of decline
of lung function
Haplotypes of 357Asn/Ser and -1607G/GG
associated with rate of decline of lung
function
Zhou et al
2004) [33]
100 COPD 98 healthy smokers Han (South
China)
MMP9 (-1562C/T) rs3918242 C/T and T allele frequencies significantly
higher in COPD patients
Zhang et al
(2005) [30]
147 COPD 120 healthy
smokers
Han (North
China)
MMP1 (-1607G/
GG)
MMP9 (-1562C/T)
MMP12 (-82A/G)
MMP12 (357Asn/
Ser)
rs1799750
rs3918242
rs2276109
rs652438
357 Asn/Asn is a risk factor for COPD
Ito et al 2005)
[34]
84 COPD 85 healthy smokers Japanese MMP9 (-1562C/T) rs3918242 T allele associated with upper lung
dominant emphysema
Hersh et al
2006) [35]
304 COPD
127 families early
onset
COPD
441 healthy
smokers
N/A
Caucasian
(USA)
MMP1 (-1607G/
GG)
MMP9 (CA
Repeat)
rs1799750
N/A
No Association found
Tesfaigzi et al
(2006) [25]
385 male COPD
with > 20 Pack
Years
N/A Caucasian
(USA)
MMP1 (-1607G/
GG)
MMP9 (279 R/Q)
MMP9 (-1562C/T)
MMP9 (CA
Repeat)
rs1799750
rs17576
rs3918242
N/A
Homozygous 279Arg associated with 3× risk
for COPD.
Haplotype containing 279Arg and CA
associated with COPD risk.
Schirmer et al
(2009) [36]
111 COPD 101 Non smoking
controls
Caucasian
(Brazil)
MMP9 (-1562C/T)
MMP12 (-82A/G)
rs3918242
rs2276109
No Association found
Table 2 Characteristics of Controls and COPD subjects
Control COPD P-value
Male (%) 63.2 69.9 0.3554
Age (yr) 60.7 ± 8.9 65.9 ± 8.2 < 0.0001
Smoking Pack Years 38.6 ± 17.4 48.7 ± 22.8 < 0.0001
Predicted FEV1 (%) 95.4 ± 11.0 43.0 ± 15.1 < 0.0001
FEV1/FVC (%) 77.8 ± 4.9 47.4 ± 12.1 < 0.0001
N 876 977
Values indicated are means ± SD. Pack Years missing for 6 persons.
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combination of databases including HapMap and Seattle
SNPs. SNPs with a minor allele frequency of less than
5% were excluded from the study, as these were likely to
be insufficiently powered to detect association. SNPs
lacking any validation status as described on the dbSNP
database were also excluded. Further narrowing of SNP
selection was based on putative function described in
the databases and predicted function by the FastSNP
web-service [22]. Where SNPs were in linkage disequili-
brium (r2 ≥ 0.8) in previously reported Caucasian popu-
lations (HapMap, National Heart Lung and Blood
Institute’s (NHLBI) Programs for Genomic Applications
European (PGA EUR) population, or Environmental
Gene Project Centre d’Etude du Polymorphisme
Humain (EGP CEPH) European population) a single
tagging SNP was chosen for genotyping, thus minimis-
ing the number of SNPs that needed to be investigated
and reducing the number of statistical tests required.
This resulted in 26 SNPs across the three genes being
selected for analysis. Information on the 26 genotyped
SNPs is indicated in Table 4. The SNPs were selected as
described below.
MMP-1
A panel of 21 validated SNPs was identified within the
gene and its promoter region. However, rs488178 was
found to be unsuitable for design and was excluded. Con-
sideration of the linkage disequilibrium between the SNPs
resulted in a final panel of 13 SNPs being genotyped, giv-
ing 87% coverage of validated SNP variation in MMP-1.
MMP-9
A panel of 23 validated SNPs was identified within the
gene and its promoter region from the databases, which
covered all known validated SNPs within the region.
However, rs25650 was found to be non-polymorphic in
the study cohort and was excluded from further analysis.
Consideration of the linkage disequilibrium between the
SNPs resulted in a final panel of 8 tagged SNPs being
genotyped, giving 96% coverage of validated SNP varia-
tion in MMP-9.
MMP-12
A panel of 17 validated SNPs was identified within the
gene and its promoter region, a selection which covered
all known validated SNPs within the region. However,
rs28360355, rs28381675 and rs28360356 were found to
be unsuitable for assay design and were excluded. Con-
sideration of the linkage disequilibrium between the
SNPs resulted in a final panel of five SNPs being geno-
typed, giving 82% coverage of validated SNP variation in
MMP-12.
Genotyping of Study Samples
Full genotyping information was available in 977 COPD
cases and 876 controls. Genotyping was carried out
commercially by K- Bioscience using KASPar, an in-
house validated competitive allele-specific polymerase
chain reaction SNP genotyping system which utilises
fluorescence resonance energy transfer quencher cas-
sette oligonucleotides. Taqman, a rapid fluorophore
based real- time PCR method, was used to genotype
SNPs found to be unsuitable for KASPar assay design.
As a quality control measure, approximately 5% of sam-
ples were genotyped in duplicate to check for concor-
dance. There was 100% concordance between the
duplicates, satisfying criteria for the assays to be
accepted for further analysis.
Statistical Analysis
Each of the SNPs in the three genes was analyzed for
Hardy-Weinberg equilibrium (HWE) using PROC
ALLELE in SAS/Genetics Release 9.1.3 [23], an empiri-
cal p-value of ≤ 0.01 was used as a cut-off, to reduce
the likelihood of reporting false positives. To examine
linkage disequilibrium, the correlation coefficient
between SNP pairs within each gene in cases and con-
trols was calculated using Haploview 4.1 [24] a software
package that computes linkage disequilibrium and hap-
lotype blocks from genotype data (figure 1).
Analyses of allele and genotype frequencies for the
three MMP genes were performed using PROC ALLELE
in SAS/Genetics. The adjusted p-values for genotype and
allele frequencies were obtained using PROC LOGISTIC
in SAS, adjusting for age, sex, smoking and centre.
As haplotypes of MMPs have been reported to be
associated with COPD or decline in lung function
[13,25], using FAMHAP18 [26] we examined haplotypes
in all possible SNP combinations based on the eight
Table 3 Characteristics of COPD patients according to GOLD classification of disease severity
GOLD Status II
Moderate
III
Severe
IV
Very Severe
P-value
Male (%) 74.7 67.5 67.2 0.0608
Age (yr) 66.1 ± 8.0 66.7 ± 8.4 64.3 ± 8.1 0.0016
Pack Years 49.2 ± 21.1 48.5 ± 22.3 48.4 ± 26.0 0.9105
Predicted FEV1 (%) 60.2 ± 5.9 40.0 ± 5.8 23.4 ± 4.3 < 0.0001
FEV1/FVC (%) 57.1 ± 7.8 45.9 ± 9.9 36.2 ± 9.4 < 0.0001
N 336 406 235
Values indicated are means ± SD. Pack years missing for 3, 2, 1 persons per classification respectively.
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Table 4 SNPs selected for genotyping
SNP No. Gene Locus tagged SNPs Location in Gene Contig position Major/Minor allele
1 MMP-1 rs2071230 rs7125320 3’ UTR 18098075 A/G
Intronic 18095326 G/T
2 MMP-1 rs2239008 rs2071232 3’ UTR 18097954 G/A
rs996999 Intronic 18093365 T/C
Intronic 18091971 C/T
3 MMP-1 rs470215 rs5854 3’ UTR 18097935 A/G
rs470747 3’ UTR 18098160 C/T
rs470132 Intronic 18097439 T/C
Intronic 18092477 G/T
4 MMP-1 rs1938901 rs5031036 Intronic 18097369 C/T
5 MMP-1 rs17881293 Intronic 18096568 A/G
6 MMP-1 rs17884110 Intronic 18095557:18095558 -/C
7 MMP-1 rs17878931 Intronic 18092379 C/A
8 MMP-1 rs10488 Exonic 18091012 G/A
Intronic 18092870 A/G
9 MMP-1 rs470358 rs505770 Intronic 18090333 C/T
10 MMP-1 rs3213460 rs476391 5’UTR 18090153 G/A
11 MMP-1 rs514921 rs644552 Promoter 18089805 A/G
12 MMP-1 rs498186 rs651159 Promoter 18089390 A/C
13 MMP-1 rs1799750 rs662028 Promoter 18088538:18088539 -/G
14 MMP-12 rs652438 Exonic (Asn357Ser) 18022346 A/G
Intronic 18024778 T/A
Intronic 18023958 G/C
Intronic 18023848 G/A
Intronic 18022569 A/G
Intronic 18018358 A/G
15 MMP-12 rs632009 rs7123600 Intronic 18020490 C/T
rs10895367 Intronic 18017018 A/G
16 MMP-12 rs11225442 Intronic 18019669 G/A
Intronic 18013855 G/C
17 MMP-12 rs28381675 rs28381684 Intronic 18018010 A/G
18 MMP-12 rs2276109 rs17368582 Upstream 18013194 A/G
rs17368659 Intronic 18021796 T/A
Exonic 18020914 T/C
Intronic 18016225 G/T
19 MMP-9 rs3918262 rs3787268 Intronic 7706054 A/G
Intronic 7704015 G/A
20 MMP-9 rs13969 rs20544 Exonic 7705117 C/A
21 MMP-9 rs2250889 rs3918251 Exonic (Pro574Arg) 7704690 C/G
22 MMP-9 rs3918256 rs3918253 Intronic 7703243 A/G
rs8113877 3’ UTR 7707164 C/T
Intronic 7701053 A/G
Intronic 7701795 T/C
Upstream 7697335 T/G
23 MMP-9 rs17576 rs3918249 Exonic (Gln279Arg) 7702509 A/G
rs3918240 Intronic 7700408 C/T
rs6965913 Upstream 7697906 C/T
Upstream 7697393 C/T
24 MMP-9 rs2274755 rs3918242 Intronic 7701976 G/T
rs13925 Promoter 7968266 C/T
rs3918261 Exonic 7707119 G/A
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SNPs in the MMP-9 gene on chromosome 20 and also
in all combinations consisting of four or fewer SNPs
from the 16 analysable SNPs (see below) in MMP-1 and
MMP-12 combined on Chromosome 11. We considered
only up to four haplotypes because of the optimal
power considerations in FAMHAP18. We compared
haplotype distributions for all cases versus controls, for
GOLD severity III and IV cases versus controls and for
GOLD severity IV only versus controls. We used as a
cut off criterion a p < 0.01 for a significance test on the
contingency table of all possible simulated haplotypes
within possible SNP combination in cases and controls.
P-values were based on 10,000 simulations and since for
this sample size the 95% confidence limits for 0.01 are +/-
0.002, we report all comparisons with a p-value less than
0.012. To allow for multiple testing we used the maximum
estimated q-value that corresponds to p-values ≤ 0.012
with a high stringency estimate of the false discovery rate
(FDR) [27,28] (using the q-value Package in R [29]).
Odds ratios for haplotype and individual SNP allele
distributions are relative to the common haplotype or
allele. The adjusted odds ratios with 95% confidence
intervals, adjusting for age, sex, smoking and centre are
estimated for haplotypes by weighted logistic regression
as described previously [19] (PROC LOGISTIC in SAS),
and for alleles by standard logistic regression.
Using PROC GLM in SAS [23] the quantitative trait
associations between SNPs or haplotypes and the phe-
notype FEV1 were tested by multivariate regression
using a similar weighted method to that used in logistic
regression [19], adjusting for age, sex, smoking and cen-
tre. The adjusted means were determined using the
LSMEANS option.
Results
Quality Control
The full list of SNPs analysed are shown in Table 4. The
overall genotype call rate was 95% (range, 92-96%), and
Figure 1 LD plot in controls of SNPs in MMPs- 1, 9 and 12. Estimated as r2 using Haploview 4.1 output. SNP codes are provided in order of
location along each gene; dark grey squares depict strong LD (1.0) with strong confidence, pale grey and white regions represent low LD, and
the r2 value is provided within each box. SNP positions are demonstrated 5’ to 3’ relative to contig postion (HuRef NCBI build 36.3).
Table 4: SNPs selected for genotyping (Continued)
rs17577 Intronic 7705876 A/G
Exonic (Arg668Gln) 7705395 G/A
rs2236416 Intronic 7702859 A/G
rs3918241 Upstream 7698025 T/A
25 MMP-9 rs3918278 Upstream 7697944 G/A
26 MMP-9 rs11697325 Upstream 7691635 A/G
SNPs are shown in 3’ to 5’ order. Contig Position numbering is relative to HuRef NCBI build 36.3. SNPs 6 and 13 (rs numbers 17884110 and 1799750 respectively)
represent an insertion/deletion polymorphism. Amino acid changes are shown where present.
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the accuracy was 100% according to duplicate genotyp-
ing of > 5% of samples. The use of high stringency cut-
offs resulted in the loss of some genotyping data and
reduction in the number of patients studied from the
original sample set. Significant deviation from HWE was
observed in controls for two MMP-1 SNPs, rs470358
and rs2071230. The assays for these two SNPs were
sub-optimal, with overlap in the signals observed for
homozygotes and hetrozygotes.
Association Analysis
Table 5 compares the genotype frequencies between all
cases and controls for the 26 SNPs analysed. There were
no significant differences at p < 0.01 in either the crude
analysis or the analysis adjusted for age, sex, smoking
levels and centre. To evaluate potential genetic
contribution to more severe manifestations of the dis-
ease, those with moderate levels of disease were
excluded from the cases and patients with either severe
or very severe disease (GOLD groups III and IV) were
compared to controls. This comparison was also per-
formed for cases with very severe disease only (GOLD
group IV). This approach enabled evaluation of the
potential underlying genetic contribution to disease
severity phenotype within the study population with
least reduction in power. While unadjusted analysis
indicated significant associations between genotype fre-
quencies of SNP 18 and more severe disease, these
became non-significant with p > 0.01 when adjusted for
age, sex, smoking and centre (Table 5). Table 6 analyses
allele relationships for all SNPs.
Table 5 MMPs -1, 12 and 9 - Genotype frequencies in Controls and Cases
Gene SNP No. Locus Genotypes Controls COPD
all cases
Unadjusted
P-value
Adjusted P-value**
MMP1 1 rs2071230 AA/AG/GG 0.85/0.13/0.02 0.85/0.14/0.00 0.01 0.16
2 rs2239008 GG/GA/AA 0.64/0.33/0.03 0.64/0.31/0.05 0.26 0.28
3 rs470215 AA/AG/GG 0.39/0.47/0.14 0.40/0.47/0.13 0.61 0.86
4 rs1938901 CC/CT/TT 0.51/0.41/0.08 0.48/0.42/0.10 0.25 0.22
5 rs17881293 AA/AG/GG 0.89/0.10/0.01 0.89/0.11/0.00 0.65 0.74
6 rs17884110 C/C/C 0.39/0.47/0.14 0.41/0.47/0.12 0.42 0.78
7 rs17878931 AA/AC/CC 0.01/0.25/0.74 0.02/0.25/0.73 0.66 0.33
8 rs10488 GG/GA/AA 0.89/0.11/0.01 0.88/0.11/0.00 0.6 0.75
9 rs470358 TT/TC/CC 0.14/0.40/0.46 0.17/0.37/0.46 0.32 0.54
10 rs3213460 GG/GA/AA 0.73/0.25/0.02 0.72/0.26/0.02 0.84 0.43
11 rs514921 AA/AG/GG 0.50/0.42/0.08 0.50/0.42/0.08 0.99 0.94
12 rs498186 AA/AC/CC 0.28/0.52/0.20 0.29/0.48/0.23 0.13 0.39
13 rs1799750 G/G/G 0.26/0.52/0.22 0.28/0.47/0.25 0.13 0.45
MMP12 14 rs652438 AA/AG/GG 0.90/0.10/0.00 0.90/0.09/0.00 0.34 0.87
15 rs632009 CC/CT/TT 0.45/0.44/0.11 0.46/0.42/0.12 0.53 0.34
16 rs11225442 GG/GA/AA 0.75/0.23/0.02 0.76/0.22/0.02 0.8 0.79
17 rs28381675 AA/AG/GG 0.88/0.11/0.00 0.87/0.12/0.01 0.5 0.22
18 rs2276109 AA/AG/GG 0.75/0.24/0.01 0.80/0.19/0.02 0.02 0.12
MMP9 19 rs3918262 AA/AG/GG 0.66/0.31/0.03 0.63/0.32/0.05 0.12 0.15
20 rs13969 CC/CA/AA 0.38/0.47/0.15 0.37/0.47/0.16 0.79 0.83
21 rs2250889 CC/CG/GG 0.93/0.07/0.01 0.93/0.07/0.00 0.45 0.68
22 rs3918256 AA/AG/GG 0.36/0.47/0.17 0.35/0.48/0.17 0.83 0.64
23 rs17576 AA/AG/GG 0.43/0.45/0.12 0.42/0.45/0.13 0.62 0.58
24 rs2274755 GG/GT/TT 0.71/0.26/0.02 0.73/0.25/0.02 0.69 0.79
25 rs3918278 GG/GA/AA 0.96/0.04/0.00 0.95/0.05/0.00 0.46 0.13
26 rs11697325 AA/AG/GG 0.39/0.46/0.15 0.37/0.47/0.16 0.64 0.64
Gene SNP No. Locus Genotypes Controls COPD
Severity IV*
Unadjusted
P-value
Adjusted P-value**
MMP12 18 rs2276109 AA/AG/GG 0.75/0.24/0.01 0.83/0.15/0.02 0.008 0.03
Gene SNP No. Locus Genotypes Controls COPD
Severity
III and IV*
Unadjusted
P-value
Adjusted P-value**
MMP12 18 rs2276109 AA/AG/GG 0.75/0.24/0.01 0.81/0.17/0.01 0.007 0.08
*For GOLD classification severity III and IV, and severity IV, only SNPs with an unadjusted significant (p-value ≤ 0.01) genotypes difference between cases and
controls are reported.
** P-values adjusted by logistic regression for age, sex, smoking and centre.
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As described in the Methods, we then examined all
possible haplotypes consisting of between two and four
SNPs in the same chromosome for differences between
the case groups defined above and controls. Adjusting
for multiple testing the only significant differences in
haplotype distributions were found when severe/very
severe (GOLD groups III and IV) cases were involved.
Table 7 shows the seven significant haplotypes together
with their unadjusted p-values. Since the haplotype
comprising SNPs 14 and 18 (p = 0.0086) is a subset of
all the other significant combinations identified, we
deduce that the significant results are a consequence of
the association of SNPs 14 and 18 with disease severity
in COPD, despite the apparently high false discovery
rate of 0.54. The low LD (r2 = 0.083) in controls
between these two SNPs indicates the separate involve-
ment of both SNPs in this association.
Table 8 shows the actual haplotypes of SNPs 14 and
18 in the MMP-12 gene and their frequencies in severe/
very severe disease (GOLD Stages III and IV) compared
to controls. For completeness the table also shows the
relationship of the alleles of each SNP alone with sever-
ity. Persons with the rare G allele of either SNPs 14 or
18 were protected against severe/very severe COPD.
Compared with the common A-A haplotype of SNPs 14
and 18, subjects with the G allele at either locus had a
Table 6 MMPs -1, 12 and 9 - Allelic frequencies in Controls and Cases
Gene SNP No. Locus Major/Minor
Alleles
Minor Allele Frequencies Unadjusted
P-value
Adjusted
P-value*
Adjusted
Odds Ratio**
Controls COPD
all cases
MMP1 1 rs2071230 A/G 0.08 0.07 0.4354 0.7453 1.045
2 rs2239008 G/A 0.20 0.20 0.6539 0.5193 0.943
3 rs470215 A/G 0.38 0.36 0.3502 0.5923 1.041
4 rs1938901 C/T 0.28 0.31 0.1248 0.2060 0.904
5 rs17881293 A/G 0.06 0.06 0.9887 0.8005 1.039
6 rs17884110 -/C 0.38 0.36 0.2574 0.5656 1.044
7 rs17878931 C/A 0.14 0.14 0.5514 0.4245 0.919
8 rs10488 G/A 0.06 0.06 0.9190 0.7863 1.042
9 rs470358 C/T 0.34 0.35 0.4928 0.6550 0.966
10 rs3213460 G/A 0.14 0.15 0.5609 0.2504 0.889
11 rs514921 A/G 0.29 0.29 0.9823 0.7495 1.026
12 rs498186 A/C 0.46 0.47 0.4443 0.3265 0.931
13 rs1799750 -/G 0.48 0.48 0.8539 0.6630 0.969
MMP12 14 rs652438 A/G 0.05 0.05 0.4773 0.6428 1.078
15 rs632009 C/T 0.33 0.33 0.9704 0.4266 1.063
16 rs11225442 G/A 0.13 0.13 0.6509 0.6242 1.053
17 rs28381675 A/G 0.06 0.07 0.3088 0.0910 0.784
18 rs2276109 A/G 0.13 0.11 0.0659 0.3243 1.115
MMP9 19 rs3918262 A/G 0.19 0.21 0.0591 0.0647 0.846
20 rs13969 C/A 0.38 0.39 0.5351 0.9600 0.996
21 rs2250889 C/G 0.04 0.04 0.4558 0.3645 1.185
22 rs3918256 A/G 0.40 0.41 0.5548 0.9810 1.002
23 rs17576 A/G 0.34 0.36 0.3622 0.4367 0.943
24 rs2274755 G/T 0.16 0.14 0.3908 0.4962 1.072
25 rs3918278 G/A 0.02 0.02 0.6433 0.0371 0.604
26 rs11697325 A/G 0.38 0.39 0.3478 0.5696 0.959
*p-values adjusted by logistic regression for age, sex, smoking and centre.
** Odds ratios are relative to the major allele.
Table 7 MMP - 1 and 12 Risk Haplotypes related to
disease GOLD severity III and IV combined versus
controls
SNP No P-value+
Haplotypes 6 10 12 13 14 16 18
2-SNP x x 0.0086
3-SNP x x x 0.0116
3-SNP x x x 0.0094
3-SNP x x x 0.0076
4-SNP x x x x 0.0110
4-SNP x x x x 0.0054
4-SNP x x x x 0.0092
+ P-values are by Monte-Carlo simulation on 10,000 runs.
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significantly reduced risk of having severe/very severe
COPD. Of note, and of importance from a population
perspective, is that, based on the distribution in controls,
18% of the European population have at least one of
these protective haplotypes, with an average risk 0.76
(95% CI: 0.61 to 0.94) times less than those with the
common haplotype.
Confining the analysis to cases only we examined the
relationship between variation in MMP-12 SNPs 14 and
18 and their haplotypes to severity of disease using
FEV1 as a severity measure. Weighted multivariate
regression models, adjusting for age, sex, smoking and
centre were used to test for the associations. Those indi-
viduals with the haplotype A-A had a significantly lower
predicted FEV1 (42.62% versus 44.79%, p = 0.0129)
when compared to patients with any haplotypes contain-
ing a G allele. We did not find a significant association
between FEV1 and the alleles in SNP 14 and SNP 18
singly.
Discussion
A number of studies have reported on the role of
genetic variants of MMPs in genetic susceptibility to
COPD or related phenotypes. However, the majority of
studies have concentrated on the three well known pro-
moter polymorphisms of these genes - MMP1-1607-/G
(rs1799750), MMP9 -1562 C/T (rs3918242) and the
MMP12-82A/G (rs2276109) in comparatively smaller
sample numbers (Table 1).
Our study reports on the largest and most extensive
screen of SNPs within the MMPs- 1, 9 and 12 genes
undertaken to date and include the three promoter
SNPs or SNPs that are in LD with the promoter SNPs
which have been previously reported, in a larger sample
size. All SNPs evaluated in the final analysis were in
HWE in controls, had high call rates and concordant
duplicates by genotyping, suggesting that this study was
not likely to be influenced by genotyping errors. All sub-
jects were of European descent and any potential effects
of population stratification were minimised by recruiting
patients and controls from each centre and confirmed
by the fact that SNP genotype frequencies in the con-
trols for each centre were found to be similar. Given the
greater level of power in our study it is unlikely that
effects of the magnitude observed in previous, less pow-
ered studies, have been missed. However, there may be
subtle differences in phenotypes and association with
quantitative traits such as lung function decline in the
previous studies that we were not able to test. This is in
part due to multiple testing issues, investigating numer-
ous phenotypes could lead to false positives. Also, phe-
notype data for some clinical endpoints such as CT
scans for emphysema has not been collected for our
population. Although, this may cause difficulties with
planning functional work, future work testing associated
SNP’s in other COPD cohorts characterised for specific
phenotypes will address this.
The patients with very severe disease had a mean age
that was less than the severe and moderate groups and
this may reflect a survival bias.
We found that MMP’s - 1 and 9 were not associated
with COPD in our populations. This is an interesting
Table 8 MMP- 12 haplotypes significantly different between GOLD Classification III and IV cases and controls
Frequency (%)
GOLD
III and IV
Controls p-value+ Odds Ratio*
(n = 641) (n = 876) Unadjusted Adjusted** 95% CI
SNP 14
(rs652438)
A 96.2 94.7 0.0536 1
G 3.8 5.3 0.71 0.76 0.52 to 1.12
SNP 18
(rs2276109)
A 90.0 87.0 0.0112 1
G 10.0 13.0 0.74 0.79 0.61 to 1.02
Haplotypes of SNP 14 and SNP 18 A-A 86.3 82.0 0.0086 1 1
A-G 9.8 12.7 0.73 0.78 0.60 to 1.00
G-A 3.8 5.1 0.70 0.74 0.50 to 1.09
G-G 0.1 0.2 0.36 0.96 0.09 to 10.63
A-A 86.3 82.0 0.0039++ 1
A-G, G-A or G-G 13.7 18.0 0.72 0.76 0.61 to 0.94
+ P-values are by Monte-Carlo simulation on 10,000 runs.
++ Adjusted for choice of the most significant 2 × 2 table with collapsed data.
* Odds ratios are relative to the common allele or haplotype.
** Adjusted for age, sex, smoking and centre.
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result as these genes have previously been implicated in
COPD by both rodent and a range of human studies. In
the previous case control association studies, many of
the associations in MMP’s 1 and 9 have been demon-
strated in non - Caucasian populations. Further to this,
some of the studies use different phenotypic end points.
For the MMP-12 gene, we identified haplotypes asso-
ciated with two SNPs, SNP 14 (rs652438) and SNP 18
(rs2276109), which showed associations with severe/very
severe COPD. The associations with GOLD Stage III
and IV disease suggest that these SNPs may play a
modifier role in disease severity. We also showed that
haplotypes of the two SNPs were significantly related to
severity within the COPD cases, as determined by the
quantitative levels of FEV1 within the cases. Those with
the haplotypes A-G, G-A or G-G had higher FEV1
levels. It is of note that, evaluation of the association of
SNP 18 (rs2276109) with COPD has been previously
examined, but no effect was seen [13,30]. This probably
reflects underpowered studies and the need to examine
disease severity. SNP 14 (rs652438) has been previously
shown to be associated with smoking induced COPD in
a Chinese cohort [30], as well as being associated with a
decline in lung function when considered as a haplotype
with the MMP-1 promoter SNP 13 (rs1799750) [13].
The recent genome wide association study (GWAS)
study in COPD by Pillai et al [31] didn’t report associa-
tion for MMP-12 in COPD even though there are SNPs
in full linkage disequilibrium with rs2276109 and
rs652438 on the illumina 550k platform used. However,
this does not preclude the SNP’s involvement in disease
as they may have significance but not to genome wide
level, access to the primary data would be of interest
regarding this. Furthermore, in our population MMP-12
SNPs are associated with severe forms of COPD after
haplotypic association, unlike the GWAS which is total
COPD cases versus control population using single SNP
association.
Although we noted a trend (p = 0.054) for association
of SNP 14 (rs652438) with disease, our strict cut-off for
significance indicates that it may require a much larger
sample size to be confident of such an association. It is
of note, however, that SNP 14 (rs652438) is a constitu-
ent of all the haplotypes found to be associated with
severe/very severe disease, suggesting that it contributes
to disease severity in COPD. It is also possible that this
locus, or genetic variants in LD with rs652438, may
affect susceptibility to COPD in the Chinese population.
Whilst we did observe three haplotypes involving SNPs
13, 14 and 18 which were associated with severe/very
severe disease (Table 7), there was no significant asso-
ciation for a 2-SNP haplotype with SNPs 13 and 14
only.
SNP 18 (rs2276109) with the alleles A/G is a known
functional variant where the A allele shows a higher affi-
nity for the transcription factor activator protein-1 (AP-
1), resulting in increased expression in gene reporter
assays. In the current study, the A-A haplotype com-
posed of SNP 18 (rs2276109) and SNP 14 (rs652438) is
over-represented in the cases, suggesting that increased
MMP-12 levels may contribute to COPD pathogenesis.
This is consistent with observations of increased MMP-
12 activity in the lungs of patients with COPD and with
observations in a rodent model of disease where MMP-
12 knock-outs are protected against smoking-induced
emphysema.
A recent paper by McAloon et al [32], screened
MMPs 1, 3 and 12 relatively comprehensively in AATD
with associations being found with gas transfer. This
could allude to MMP - 12’s role in parenchymal disease
pathophysiology rather than airways disease, especially
when considered with association in this study against
severe forms of COPD and in previous studies with
emphysema.
Conclusions
While this study provides suggestive evidence for a con-
tribution of genetic variation in MMP-12 to disease
severity in COPD, we do not find evidence for the invol-
vement of MMPs- 1 and 9 in COPD. This merits
further investigation of MMP-12 associations in similar
or larger cohorts.
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